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CLINICAL CASE STUDY
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A 56-year-old female with history of stage IIA adenosquamous lung carcinoma treated
13months prior to presentation with lobectomy, mediastinal lymph node dissection,
and adjuvant chemotherapy, presented for several weeks of worsening dyspnea. Exam
was non-focal aside from tachycardia. Computed tomography of the chest revealed a
large 4 cm5 cm mass in the bilateral ventricular myocardium. There was also evidence
of metastatic disease elsewhere in the body, including a supraclavicular lymph node
that was positive for metastatic adenosquamous lung carcinoma. She started whole
heart radiotherapy and was to commence chemotherapy but passed away. This report
discusses important aspects of diagnosis of this not uncommon condition that many
oncologists may come across. We also discuss differential diagnosis of an isolated
intracardiac mass as first-diagnosis presentations, and discuss the great importance of
multidisciplinary cardio-oncologic management and clinical prioritization.
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Introduction
A 56-year-old woman presented for several weeks of worsening dyspnea on exertion and non-
productive cough. She had a history of stage IIA adenosquamous carcinoma of the lung (left lower
lobe) treated 13months ago with lobectomy and mediastinal lymph node dissection and adjuvant
chemotherapy (carboplatin/paclitaxel and subsequently pemetrexed), with no evidence of disease on
multiple subsequent computed tomography (CT) scans. After her initial diagnosis, she had ceased
smoking and had previously overall felt well. Her weight had been stable and had no pain other than
left-sided chest pain when coughing. She also endorsed night sweats and palpitations.
On examination, lungs were clear to auscultation bilaterally and cardiac exam was unremarkable
except for mild tachycardia. The remainder of the examination was normal with exception of a firm
but mobile 1 cm lymph node palpated in the left supraclavicular fossa.
On presentation, CT chest with contrast (Figure 1) demonstrated normal postoperative changes
of left lower lobectomy. There was a large intracardiac mass, 4 cm 5 cm, involving bilateral ven-
tricular myocardium. Also present was left-sided supraclavicular lymphadenopathy and irregular
pericardial thickening suggestive of pericardial tumor involvement.
Biopsy of the left supraclavicular lymph node revealed a metastasis of the patient’s non-small cell
lung cancer (NSCLC), as depicted in Figure 2. Thus, though the cardiac mass was not biopsied,
its radiological appearance (1) as well as relatively quick growth to 4 5 cm size in 13months was
concerning for tumor recurrence.
She was to have port placement for chemotherapy, and started whole heart radiotherapy at a
dose of 3,000 cGy in 12 fractions of 250 cGy each. Unfortunately, this patient completed a portion
of radiotherapy (1,750 cGy) and nearly 3weeks after diagnosis, was to undergo port placement for
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FIGURE 1 | Axial (left), coronal (center), and sagittal (right) CT with contrast images showing intracardiac metastasis.
FIGURE 2 | Hematoxylin-eosin staining of left supraclavicular lymph
node demonstrating recurrent NSCLC.
systemic therapy (nivolumab) but passed away from supraventric-
ular tachycardia, which progressed to pulseless cardiac arrest.
Background
Cardiac metastases, most commonly from lung cancer (30–40%),
are not as uncommon as expected, with incidences up to 18% in
the literature; the average incidence around 10% of all patients
with malignancies seems less in clinical practice, likely due to
most metastases having been discovered incidentally and smaller
in size (2).
There have been several case reports of intracardiac metastases
from various types of cancers, including lung cancer as in the
present case (3). As with this patient, metastases can be symp-
tomatic, or more commonly, asymptomatic (4). Though diagnosis
is usually by echocardiography, incidental discoveries have been
shown with other modalities, such as endobronchial ultrasound
(5). Tumors can be located in any atrial or ventricular chamber,
or possibly even multiple tumor foci within a single chamber at a
time (6). Treatment is very variable from study to study, and thus is
quite controversial. It is usually done on a case-by-case basis, and
treatments have ranged from surgical resection (7), chemotherapy
(8), and even primary radiotherapy (9).
Discussion
Though tumor recurrence in this patient was the most likely diag-
nosis, first-timediagnoses in similar patients provide a discussion-
worthy differential diagnosis. Tumor thrombus is an important
item on the differential diagnosis, also because coagulopathy
of malignancy can present in such a manner and would result
in entirely different management including anticoagulation (10).
Cardiac abscesses can get large and also be associated with
regional lymphadenopathy, but are usually non-homogeneous on
imaging with non-erosive features, and are far less likely than
tumor recurrences. Lymphoma is the secondmost common cause
of metastatic cardiac tumors, and could be likely given concurrent
lymphadenopathy in other areas, but a 13-month interval may
not be an optimal timing of developing secondary cancer, and
new primary lymphoma would not be the most common cause
as much as an NSCLC recurrence (11). Biopsy confirmed that
recurrence was from the NSCLC and not lymphoma. Other items
on the differential diagnosis that are important to consider are
second primary lung cancer or a local recurrence that extrinsically
invades the heart, and less likely primary heart tumors, due to
differences in management accordingly.
Initial workup in such patients is hence very important, because
chest imagingmaynot even be performed atmany centers if symp-
toms canbe easily explained by the vastlymore commonexacerba-
tions of congestive heart failure (CHF) and/or chronic obstructive
pulmonary disease (COPD). Indeed, many patients with lung
cancer history also have comorbidities including CHF and COPD
forwhich symptomatic treatment could delay or prevent diagnosis
of an intracardiac mass if there were no other findings on physical
examination (such as supraclavicular lymphadenopathy in this
patient). With history of the more aggressive adenosquamous
lung cancer, however, greater diagnostic suspicion is certainly
warranted (12).
Because intracardiac metastases can be hemodynamically
threatening, management is important for clinicians to be aware
of; multidisciplinary management by a team of medical oncol-
ogists, cardiologists, radiation oncologists, and pulmonologists
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is crucial. Maintenance of hemodynamic stability is of greatest
concern; this patient had severely reduced ventricular systolic
function. As a result, this patient’s tachycardia was likely compen-
satory; thus, beta-blockers make the clinical condition worse, so
medication modification is also important.
Treatment options must also be handled by a multidisci-
plinary team. Radiotherapy is efficacious for quick cell killing,
so whole heart radiotherapy was recommended. Whole heart
radiotherapy is the most common form of radiotherapy exis-
tent in the literature, including fraction sizes ranging mostly
from 200 to 300 cGy (discussed subsequently). Chemotherapy
(e.g., carboplatin/paclitaxel) versus newer biologic agents, such
as the PD-1 inhibiting antibody nivolumab, which has shown
efficacy in previously treated and advanced NSCLC, should also
be considered (13).
Prognosis for patients with intracardiac metastases is corre-
spondingly limited, with limited clinical experience. It is rea-
sonable to conclude that prognosis for patients with intracardiac
metastases is poor, likely because the disease is metastatic to
begin with. A suggestive and relatively large study from Taiwan
(14) retrospectively analyzed 48 patients with intracardiac metas-
tases from hepatocellular carcinoma (HCC) and compared out-
comes with age-, stage-, and gender-matched HCC patients. The
median survival was not different (p= 0.67) between those with
intracardiac metastases (102 days) and the HCC patients without
intracardiac metastases (68 days). This suggests that metastatic
cancer is likely the cause of death in these patients, regardless
of whether intracardiac involvement is present, provided acute
aberrant hemodynamics is stabilized. However, it is known from
another retrospective report of 11 patients that heart radiother-
apy can potentially improve survival (15). Though not statisti-
cally analyzed, radiotherapy (of varied doses, 25–60Gy) improved
median survival to 10.5months as compared with 3.5months
without radiotherapy. Thus, with more clinical experience, it will
also be important to better delineate radiotherapy doses in these
patients, for which there are no standard guidelines at present.
Concluding Remarks
In summary, intracardiac metastases are not uncommon and are
serious complications of many tumors, most commonly lung can-
cers. Diagnosis can often be difficult if imaging is not obtained, so
clinical suspicion needs to be exercised especially with a primary
tumor with poor prognostic factors. Multidisciplinary cardio-
oncologic management with prioritization on cardiovascular sta-
bility and rapid tumor killing for symptomatic cardiovascular
benefit is warranted, as are systemic therapy options for likely
other sites of involvement.
Consents and Approvals
Institutional Review Board approval is not required for single-
patient cases at the University of Nebraska Medical Center. Con-
sent was obtained from the patient’s next of kin for this report.
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